Biocon gets U.S. FDA nod for Yesintek autoinjector format

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.3%Reaction day

₹412.00

prior close

₹413.50

announcement price

After-mkt

timing

Nifty Midcap 150market-0.4%+1.7% vs market

Pharmaceuticals peers, median of 175sector+0.0%+1.3% vs sector

On the reaction day the stock moved 1.7 pts more than Nifty Midcap 150 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

-0.2

15m

+0.0

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.3-0.4+1.7+0.0+1.3

Next day

+0.2-0.6+0.8-0.6+0.7

+0.1-0.3+0.4-0.2+0.3

+0.9-0.2+1.1-0.2+1.1

-0.7-0.1-0.6-0.4-0.3

+0.6+0.3+0.2-0.7+1.3

+0.9+0.2+0.7-0.6+1.5

15d

-4.8-1.6-3.2+1.7-6.5

-5.9-2.4-3.5+1.8-7.6

-17.5-8.3-9.1-3.9-13.6

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 175Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon's U.S. subsidiary received supplemental U.S. FDA approval for Yesintek (ustekinumab-kfce) single-dose prefilled autoinjector in 45 mg/0.5 ml and 90 mg/ml strengths. The drug treats moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. Yesintek was originally approved in November 2024. This new delivery format strengthens Biocon's U.S. immunology portfolio.

Likely market impact

New patient-friendly delivery format expands Biocon's U.S. immunology portfolio, which could support revenue growth.